Switch theme
Sign up to access all valuation multiples
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
2007
4.4K+
LTM Revenue $1.8B
LTM EBITDA -$243M
$20.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Natera has a last 12-month revenue (LTM) of $1.8B and a last 12-month EBITDA of -$243M.
In the most recent fiscal year, Natera achieved revenue of $1.7B and an EBITDA of -$148M.
Natera expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Natera valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.8B | XXX | $1.7B | XXX | XXX | XXX |
| Gross Profit | $1.1B | XXX | $1.0B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | -$243M | XXX | -$148M | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -9% | XXX | XXX | XXX |
| EBIT | -$274M | XXX | -$222M | XXX | XXX | XXX |
| EBIT Margin | -15% | XXX | -13% | XXX | XXX | XXX |
| Net Profit | -$238M | XXX | -$190M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Natera's stock price is $158.
Natera has current market cap of $21.5B, and EV of $20.7B.
See Natera trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $20.7B | $21.5B | XXX | XXX | XXX | XXX | $-1.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Natera has market cap of $21.5B and EV of $20.7B.
Natera's trades at 12.2x EV/Revenue multiple, and -140.1x EV/EBITDA.
Equity research analysts estimate Natera's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Natera has a P/E ratio of -90.6x.
See valuation multiples for Natera and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $21.5B | XXX | $21.5B | XXX | XXX | XXX |
| EV (current) | $20.7B | XXX | $20.7B | XXX | XXX | XXX |
| EV/Revenue | 11.4x | XXX | 12.2x | XXX | XXX | XXX |
| EV/EBITDA | -85.5x | XXX | -140.1x | XXX | XXX | XXX |
| EV/EBIT | -75.6x | XXX | -93.3x | XXX | XXX | XXX |
| EV/Gross Profit | 18.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -90.6x | XXX | -113.1x | XXX | XXX | XXX |
| EV/FCF | -704.6x | XXX | 353.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNatera's last 12 month revenue growth is 17%
Natera's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Natera's rule of 40 is -20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Natera's rule of X is 29% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Natera and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -9% | XXX | XXX | XXX |
| EBITDA Growth | -3% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -20% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 29% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Natera acquired XXX companies to date.
Last acquisition by Natera was XXXXXXXX, XXXXX XXXXX XXXXXX . Natera acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Natera founded? | Natera was founded in 2007. |
| Where is Natera headquartered? | Natera is headquartered in United States of America. |
| How many employees does Natera have? | As of today, Natera has 4.4K+ employees. |
| Who is the CEO of Natera? | Natera's CEO is Mr. Steven Leonard Chapman. |
| Is Natera publicy listed? | Yes, Natera is a public company listed on NAS. |
| What is the stock symbol of Natera? | Natera trades under NTRA ticker. |
| When did Natera go public? | Natera went public in 2015. |
| Who are competitors of Natera? | Similar companies to Natera include e.g. EZZ Life Science, Epigenomics, ToolGen, 4basebio. |
| What is the current market cap of Natera? | Natera's current market cap is $21.5B |
| What is the current revenue of Natera? | Natera's last 12 months revenue is $1.8B. |
| What is the current revenue growth of Natera? | Natera revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Natera? | Current revenue multiple of Natera is 11.4x. |
| Is Natera profitable? | Yes, Natera is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Natera? | Natera's last 12 months EBITDA is -$243M. |
| What is Natera's EBITDA margin? | Natera's last 12 months EBITDA margin is -13%. |
| What is the current EV/EBITDA multiple of Natera? | Current EBITDA multiple of Natera is -85.5x. |
| What is the current FCF of Natera? | Natera's last 12 months FCF is -$29.4M. |
| What is Natera's FCF margin? | Natera's last 12 months FCF margin is -2%. |
| What is the current EV/FCF multiple of Natera? | Current FCF multiple of Natera is -704.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
